Isofol Q2 2022: Uncertain path forward - Redeye

Redeye comments on Isofol’s Q2 2022 report, roughly three weeks after the company communicated that its phase III AGENT trial failed to reach its primary ORR endpoint or key secondary PFS endpoint with statistical significance. We judge that Isofol’s future is highly uncertain and remain cautious until final study data and regulatory feedback suggest a possible path forward.

Länk till analysen i sin helhet: https://www.redeye.se/research/852818/isofol-q2-2022-uncertain-path-forward?utm_source=finwire&utm_medium=RSS